Polyclonal Antibody to Glial Fibrillary Acidic Protein (GFAP)
Intermediate Filament Protein
- Product No.PAA068Mu01
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- SourcePolyclonal antibody preparation
- Ig Type IgG
- PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
- Immunogen RPA068Mu01-Recombinant Glial Fibrillary Acidic Protein (GFAP)
- Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
- Organism Species MoreHomo sapiens (Human), Rattus norvegicus (Rat)
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
- DownloadInstruction Manual
- UOM 20µl100µl 200µl 1ml 10ml
For more details, please contact local distributors! US$ 227
For more details, please contact local distributors! US$ 324
For more details, please contact local distributors! US$ 810
For more details, please contact local distributors! US$ 3240
For more details, please contact local distributors!
The antibody is a rabbit polyclonal antibody raised against GFAP. It has been selected for its ability to recognize GFAP in immunohistochemical staining and western blotting.
Western blotting: 0.5-2µg/mL;1:180-740
Optimal working dilutions must be determined by end user.
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
- Antibody Labeling Customized Service
- Protein A/G Purification Column
- Staining Solution for Cells and Tissue
- Positive Control for Antibody
- Tissue/Sections Customized Service
- Phosphorylated Antibody Customized Service
- Immunohistochemistry (IHC) Experiment Service
- Immunocytochemistry (ICC) Experiment Service
- Flow Cytometry (FCM) Experiment Service
- Immunoprecipitation (IP) Experiment Service
- Immunofluorescence (IF) Experiment Service
- PBS Buffer
- DAB Kit
- SABC Kit
- Long-arm Biotin Labeling Kit
- Real Time PCR Experimental Service
|Journal of Occupational Health||Effects of Exposure to 1-Bromopropane on Astrocytes and Oligodendrocytes in Rat Brain Pubmed: 23183024|
|Morfovirtual 2014||EFECTO PROTECTOR DEL TRATAMIENTO CON NEUROEPO SOBRE LA GLIA DE LA CORTEZA CEREBRAL EN RATONES TRANSGéNICOS CON LA ENFERMEDAD DE ALZHEIMER. Sld:Source|
|Annals of Anatomy||Effect of memantine, a NMDA receptor blocker, on ethambutol-induced retinal injury PubMed: 26704355|
|Mediators of Inflammation||IL-4 Inhibits IL-1β-Induced Depressive-Like Behavior and Central Neurotransmitter Alterations PubMed: 26417153|
|Neurochem Res||Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat PubMed: 26700436|
|Cell Mol Neurobiol||Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease PubMed: 26119304|
|Sleep and Biological Rhythms||Relationship of orexin (hypocretin) system and astrocyte activation in Parkinson's disease with hypersomnolence Doi: 10.1111|
|Cellular and Molecular Neurobiology||Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease Pubmed:26119304|
|Ann Anat||Effect of memantine: A NMDA receptor blocker, on ethambutol-induced retinal injury Pubmed:26704355|
|United States Patent Application||ESTROGENIC COMPONENTS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS y2016:0101116.html|
|Clinical Research||Human plasma glial fibrillary acidic protein and heat shock protein 27 concentrations in acute moderate-intensity aerobic exercise with different duration a825e1e27b0221df9a627769c0f614432e92.pdf|
|Medical Journal of Indonesia||Comparison of GFAP and HSP27 concentrations in acute moderate-intensity aerobic exercise of different duration 2031884|
|Peptides.||Carnosine ameliorates cognitive deficits in streptozotocin-induced diabetic rats: Possible involved mechanisms. pubmed:27777064|
|european journal of pharmacology||Garlic active constituent s-allyl cysteine protects against lipopolysaccharide-induced cognitive deficits in the rat: Possible involved mechanisms. pubmed:27915041|
|european journal of pharmacology||Troxerutin exerts neuroprotection in 6-hydroxydopamine lesion rat model of Parkinson's disease: Possible involvement of PI3K/ERβ signaling. pubmed:28284752|
|biomedicine & pharmacotherapy||Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat. pubmed:28199883|
|J Endocrinol.||Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study. pubmed:27799463|
|IOS Press Content Library||An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's … articles:journal-of-alzheimers-disease|
|Tierärztliche Hochschule Hannover||Evaluierung von Biomarkern im Liquor cerebrospinalis bei paraplegischen Hunden mit Rückenmarksverletzung :|
|Nigerian Journal of Clinical Practice||Utilization of Glial Fibrillary Acidic Protein and Galectin-3 in the Diagnosis of Cerebral Infarction Patients with Normal Cranial Tomography pubmed:28406123|
|Cytokine||Soy isoflavone genistein attenuates lipopolysaccharide-induced cognitive impairments in the rat via exerting anti-oxidative and anti-inflammatory effects pubmed:29102164|
|Biomedicine & pharmacotherapy||Berberine ameliorates intrahippocampal kainate-induced status epilepticus and consequent epileptogenic process in the rat: Underlying mechanisms pubmed:28061403|
|Experimental gerontology||The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling. pubmed:29107062|